16.10.2023 - - New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte s PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations - - Expanded Collaboration Builds on Vaxcyte’s Current Strategy to Conduct Initial Commercial . Seite 1
Credit: Free Vector
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.
According to Charles Christy, head of commercial solutions, Ibex Dedicate, Lonza, the response to the COVID-19 pandemic has been driving progress with several vaccine formats including inactivated vaccines, nonreplicating vaccines, adjuvanted recombinant protein vaccines, DNA and mRNA vaccines, live attenuated vaccines, protein subunit vaccines, T cell–based vaccines, and more.
It is clear that the COVID-19 emergency is speeding vaccine development. It also appears that vaccine development may gain enough momentum to overcome new challenges once COVID-19 is contained.
The Sleeping Giants of Vaccine Production Awaken
Moderna and Lonza have entered a 10-year strategic collaboration to facilitate the large-scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) and additional future Moderna products at Lonza’s facilities in the United States and Switzerland. This image shows a large-scale manufacturing facility at Lonza’s Ibex Dedicate facility in Visp, Switzerland. [Lonza]
The Sleeping Giants of Vaccine Production Awaken
Stirred to action by the COVID-19 pandemic, vaccine stalwarts mobilize new formats, accelerate development, and scale up manufacturing
February 3, 2021
Moderna and Lonza have entered a 10-year strategic collaboration to facilitate the large-scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) and additional future Moderna products at Lonza’s facilities in the United States and Switzerland. This image shows a large-scale manufacturing facility at Lonza’s Ibex Dedicate facility in Visp, Switzerland. [Lonza]
Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months.
It likely is safe to say no professionals in drug development and manufacturing has a reliable crystal ball that can provide a crystal-clear picture of exactly what will happen in the coming 12 months. However, seasoned and savvy professionals can offer educated opinions, and advice on preparing for what might lie ahead.
To get a clearer perspective on what 2021 might have in store for the pharma field, Outsourcing-Pharma (OSP) checked in with three Lonza executives, asking their thoughts on 2020 as well as the new year: